# Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

> **NCT03879837** · PHASE3 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 1902 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone propionate pressurized metered dose inhaler
- **DRUG:** Flovent HFA pressurized metered dose inhaler
- **DRUG:** Placebo pressurized metered dose inhaler

## Key facts

- **NCT ID:** NCT03879837
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-07-09
- **Target enrollment:** 1902 (ACTUAL)
- **Last updated:** 2021-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879837, "Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03879837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*